Patents-Review.com
ClassID:

116764 ⎘

C12Y304/14009 - CPC Classification

Classification description:

Hydrolases acting on peptide bonds, i.e. peptidases (3.4); Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14) Tripeptidyl-peptidase I (3.4.14.9)

Recent Application in this class:
#1
20260078406
2026-03-19

GENE THERAPY FOR CEROID LIPOFUSCINOSES

 #2
20250338833
2025-11-06

METHODS FOR TREATING LYSOSOMAL STORAGE DISEASES

 #3
20240158772
2024-05-16

METHODS FOR TREATING LYSOSOMAL STORAGE DISEASES

 #4
20240091380
2024-03-21

GENE THERAPY FOR NEURONAL CEROID LIPOFUSCINOSES

 #5
20230383312
2023-11-30

GENE THERAPY FOR CEROID LIPOFUSCINOSES

 #6
20230364206
2023-11-16

GENE THERAPY FOR OCULAR MANIFESTATIONS OF CLN2 DISEASE

 #7
20220273775
2022-09-01

Methods for Treating CLN2 Disease in Pediatric Subjects

 #8
20220184188
2022-06-16

AAV VECTOR TREATMENT METHODS FOR LATE INFANTILE NEURONAL CEROID LIPOFUSCINOSIS TYPE 2

 #9
20220174981
2022-06-09

PROLINE TOLERANT TRIPEPTIDYL PEPTIDASES AND USES THEREOF

 #10
20220098243
2022-03-31

Selective recovery

 #11
20220064288
2022-03-03

Anti-Human Transferrin Receptor Antibody Permeating Blood-Brain Barrier

 #12
20210120845
2021-04-29

METHOD FOR PRODUCING A PROTEIN HYDROLYSATE EMPLOYING AN ASPERGILLUS FUMIGATUS TRIPEPTIDYL PEPTIDASE

 #13
20200353059
2020-11-12

TPP-1 formulations and methods for treating CLN2 disease

 #14
20200245642
2020-08-06

USE OF PROLINE TOLERANT TRIPEPTIDYL PEPTIDASES IN FEED ADDITIVE COMPOSITIONS

 #15
20200239908
2020-07-30

Gene therapy for ceroid lipofuscinoses

 #16
20200087353
2020-03-19

Selective recovery

 #17
20190292230
2019-09-26

Selective recovery

 #18
20190284576
2019-09-19

SCALABLE HIGH RECOVERY METHODS FOR PRODUCING HIGH YIELD RECOMBINANT ADENO-ASSOCIATED VIRAL (rAAV) VECTOR AND RECOMBINANT ADENO-ASSOCIATED VIRAL (rAAV) VECTORS PRODUCED THEREBY

 #19
20190269797
2019-09-05

GENE TRANSFER COMPOSITIONS, METHODS AND USES FOR TREATING NEURODEGENERATIVE DISEASES

 #20
20190216905
2019-07-18

TPP-1 formulations and methods for treating CLN2 disease

 #21
20190144509
2019-05-16

Selective recovery

 #22
20180236105
2018-08-23

METHODS FOR TREATING NEURODEGENERATIVE DISEASES USING GENE THERAPY TO DELAY DISEASE ONSET AND PROGRESSION WHILE PROVIDING COGNITIVE PROTECTION

 #23
20180230186
2018-08-16

Selective recovery

 #24
20180171012
2018-06-21

Anti-human transferrin receptor antibody permeating blood-brain barrier

 #25
20170325479
2017-11-16

PROLINE TOLERANT TRIPEPTIDYL PEPTIDASES AND USES THEREOF

 #26
20170240885
2017-08-24

Selective recovery

 #27
20170166926
2017-06-15

Targeting peptides for directing adeno-associated viruses (AAVs)

 #28
20170000729
2017-01-05

METHODS AND COMPOSITIONS FOR TREATMENT OF NEURODEGENERATIVE DISEASES

 #29
20160324942
2016-11-10

TPP-1 formulations and methods for treating CLN2 disease

 #30
20150079038
2015-03-19

Recombinant AAV capsid protein

 #31
20130022981
2013-01-24

Human lysosomal protein and methods of its use

 #32
20120308544
2012-12-06

Substances and Methods for the Treatment of Lysosmal Storage Diseases

 #33
20120014935
2012-01-19

Methods of treating a deficiency of functional tripeptidyl peptidase I (CLN2) protein

 #34
20110166074
2011-07-07

CLN2 TREATMENT OF ALZHEIMER'S DISEASE

 #35
20110014172
2011-01-20

Methods of treating a deficiency of functional tripeptidyl peptidase I (CLN2) protein

 #36
20090075315
2009-03-19

Human lysosomal protein and methods of its use

 #37
20090022701
2009-01-22

Methods of reducing storage products using tripeptidyl peptidase I (CLN2) protein

 #38
20080051358
2008-02-28

Method of expressing human lysosomal protein in brain cells